Engineering of CAR-T cells that overcome MYC-dependent immunosuppression in a genetically engineered mouse model of pancreatic cancer (B05)

• Subject Area: Hematology, Oncology ; Gastroenterology
• Term: since 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 452881907

CAR-T cell therapies are still not curative in multiple myeloma due to reduced T cell fitness and tumor immune escape. We will address these challenges by generating different types of multi-antigen specific NeoTCR- and CAR-modified cell products, also using orthotopic receptor replacement. We aim to improve their effector cell fitness through pharmacological interventions and investigate the interplay of these receptor-modified T cells with additional immune cells in the context of MYC deregulation and antigen spreading.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 338: LETSIMMUN - Lymphocyte Engineering for Therapeutic Synthetic Immunity
• Applicant Institution: Technische Universität München
• Project Heads: Eva Bräunlein, Ph.D., since 1/2026; Dr. Sophia Danhof; Professor Dr. Martin Eilers, until 12/2025